Why are migraineurs more depressed?  A review of the factors contributing to the comorbidity  of migraine and depression = Miért gyakoribb a depresszió migrénesekben? A migrén és a depresszió komorbiditásához járuló faktorok  áttekintése by Baksa, Dániel et al.
REVIEW  Daniel Baksa, Xenia Gonda and Gabriella Juhasz
Neuropsychopharmacologia huNgarica 2017. XiX. évf. 1. szám Neuropsychopharmacologia huNgarica 2017. XiX. évf. 1. szám 37
Why are migraineurs more depressed?  
A review of the factors contributing to the comorbidity  
of migraine and depression
The comorbidity of migraine and depression is well-known. Patients with both conditions 
show stronger headache-related symptoms, a more severe clinical course and higher risk 
for migraine chronification. Therefore, it’s important to identify factors underlying comorbid 
migraine and depression. The growing body of literature suggests complex, biopsychosocial 
mechanisms in the background, including shared genetic risk factors and abnormal brain 
mechanisms, and also different environmental (stress) and psychological variables (for exam-
ple: rumination, neuroticism). In this short review we summarize the most important findings 
regarding the interacting factors in the pathomechanism of the co-existence of migraine and 
depression. Finally, we conclude some therapeutical considerations regarding treatment of 
patients with the migraine-depression phenotype.
(Neuropsychopharmacol Hung 2017; 19(1): 37–44)
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There is a well-known connectivity between mi-graine and several psychopathological illnesses, 
especially mood and anxiety disorders. In patients 
with major depressive disorder (MDD) the risk of 
comorbid migraine is two to three times higher than 
in non-MDD controls (Ligthart et al., 2014). The 
connection between migraine and anxiety is simi-
larly strong, and the association of MDD and anxiety 
might be particularly strong in persons with comor-
bid migraine (Breslau et al., 1994). Others (Oede-
gaard and Fasmer, 2005; Oedegaard et al., 2010) also 
highlight the high deegree of comorbidity between 
migraine and bipolar disorder, and the possibility that 
migraine in patients with unipolar depression might 
be a bipolar spectrum trait (because their symptom 
profile resembles more the symptom profile of pa-
tients with bipolar disorder compared to the pure 
MDD-group).
Some suggest a specific order of onset: anxiety 
disorders tend to precede migraine, whereas depres-
sion tends to follow it; but a bidirectional relation-
ship between depression and migraine seems to be 
the most plausible model: each condition increases 
the incidence of the other (Buse et al., 2013). It has 
been demonstrated that many health conditions in-
crease the risk of depression and in turn depression 
negatively affects the treatment outcome and the 
associated disability rate in these patients (Prince et 
al., 2007). There is also evidence suggesting that mi-
graineurs with comorbid psychiatric disorders have 
worse headache-related symptoms (e.g., frequency, 
disability) and lower quality of life than migraineurs 
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without psychiatric comorbidities, and depression 
and anxiety seem to be risk factors for migraine 
chronification (Buse et al., 2013). Allodynic symp-
toms and higher susceptibility to migraine triggers 
were found to be related to anxiety and depression 
symptoms among migraineurs (Baldacci et al., 2015). 
Patients with comorbid migraine and depression 
also have a more serious clinical course (Cahill and 
Murphy, 2004) and are less likely to respond to selec-
tive serotonin reuptake inhibitors (SSRIs) (Leuchter 
et al., 2010). 
A growing body of evidence suggests complex, 
biopsychosocial mechanisms in the background of 
the comorbidity between migraine and depression. 
In this short review we collect the most relevant pos-
sible factors underlying this relationship of the two 
disorders.
SHARED GENETIC FACTORS  
IN THE COMORBIDITY BETWEEN MIGRAINE 
AND DEPRESSION
Both depression and migraine are around 40-50% 
heritable, and both conditions have a polygenic 
background (Ligthart et al., 2014). It has been hy-
pothesized that common genetic variants can pre-
dispose to comorbidity of migraine, anxiety and 
depression. Twin studies suggest that about 20% of 
the variability in depression and migraine headaches 
was due to shared genes (Ligthart et al., 2010; Schur 
et al., 2009). 
Altered serotonin neurotransmission is a key find-
ing in both depression and migraine, and most previ-
ous hypotheses about the pathomechanism of comor-
bidity in these disorders were built on this observation 
(Cahill and Murphy, 2004). Genetic findings support 
the involvement of the serotonin system in shared 
biological processes: one of the main candidates is 
the serotonin transporter (5HTT) gene (SLC6A4) 
that has a functional polymorphism in the promoter 
region (5HTTLPR): the short form (s) of which is 
transcriptionally less active (Lesch et al., 1996). This 
short form (s) is associated with anxiety-related traits 
(Gonda et al., 2009; Lazary et al., 2011; Lazary et al., 
2009; Lazary et al., 2008; Lesch et al., 1996; Munafo 
et al., 2009) and risk of depression (Caspi et al., 2010; 
Caspi et al., 2003; Gonda et al., 2005). Furthermore, 
it was demonstrated that the s allele also increases 
the risk of migraine (Gonda et al., 2007; Juhasz et 
al., 2003; Schurks et al., 2010). On the other hand, 
fundamental differences exist at the 5HT receptor 
level between these two conditions that questions the 
serotonergic explanation of the increased comorbid-
ity between migraine and depression, which will be 
explained in the next section.
A dopamine dysfunction was also suggested as 
an underlying cause of the comorbidity between 
migraine and depression (Buse et al., 2013), but the 
literature on alterations in dopamine genetics in mi-
graine shows highly mixed results (Akerman and 
Goadsby, 2007).
The endocannabinoid system also seems to have 
a role in the comorbidity of migraine and depression. 
The cannabinoid receptor 1 (CB1) gene (CNR1) was 
found to be a risk factor for depression through a high 
neuroticism-low agreeableness phenotype (Juhasz et 
al., 2009a); and the CNR1 gene also has a significant 
effect on migraine (Juhasz et al., 2009b; Juhasz et 
al., 2017).
A study investigating the shared genetics of mi-
graine and anxious depression (Ligthart et al., 2010) 
showed that the heritability of migraine was higher 
when it wasn’t accompanied by comorbid depres-
sion. The researchers concluded that some depression-
related disturbances in the brain could also be a risk 
factor for migraine, and thus depressed individu-
als would still develop migraine regularly without 
a severe genetic predisposition to migraine. Indeed, 
the genetic background of migrane patients with co-
morbid depression resembled more to depression 
than migraine using a polygenic risk score analysis 
(Ligthart et al., 2014). 
Another study (Oedegaard et al., 2010) suggested 
that some genes may predispose to both bipolar dis-
order and migraine: a susceptibility locus was identi-
fied on chromosome 20 pointing to a genetic overlap 
between migraine and bipolar disorder. The authors 
highlighted that the identified overlapping region 
harbors a potassium-dependent sodium/calcium 
exchanger gene, SLC24A3, which has an important 
role in neuronal calcium homeostasis and electrical 
conduction. Based on their findings the researchers 
suggested that ionic disturbances seem to be relevant 
in the migraine-bipolar disorder phenotype.
BRAIN MECHANISMS OF COMORBIDITY 
BETWEEN MIGRAINE AND DEPRESSION
Modern neuroimaging studies showed abnormal 
function, structure, and connectivity of brain regions 
that could contribute to the comorbidity of migraine 
and psychiatric disorders (Minen et al., 2016). 
As we mentioned, there are some basic differences 
between depression and migraine at the 5HT receptor 
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level. Positron emission tomography (PET) studies 
demonstrated that in depression, both in the acute 
phase and in remitted patients, there is an extensive 
reduction of 5HT1A receptors in the brain (Drevets 
et al., 2007; Sharp and Cowen, 2011). In parallel 
with this, neuroendocrine challenge paradigms in 
depressed patients repeatedly found blunted cortisol 
response to agents that acutely increase extracellular 
5HT concentrations (Sharp and Cowen, 2011). In 
contrary to depression, migraine patients show in-
creased 5HT1A receptor density (Lothe et al., 2008; 
May, 2009) and they are sensitive to brain serotonin 
increasing agents and usually respond with a delayed 
migraine attack and an augmented cortisol response 
compared to controls (Panconesi, 2008). In addition, 
the first-line antidepressant drugs in the treatment 
of major depression, the SSRIs, are not effective in 
preventing migraine attacks (Evers et al., 2009; Moja 
et al., 2005; Panconesi, 2008). In contrary, the most ef-
fective migraine prophylactic drugs, the beta-blockers, 
have pro-depressive side effects. 
The above results, therefore, don’t support the 
serotonergic explanation of depression-migraine 
comorbidity. FMRI studies, however, investigating 
the effect of 5HTTLPR and emotional information 
processing repeatedly found increased amygdala ac-
tivation in s allele carriers for emotionally salient 
stimuli (Hariri et al., 2002; Munafo et al., 2008). In 
addition, comparing s carriers with ll homozygotes 
in healthy volunteers the connectivity between the 
amygdala and the ventro-medial prefrontal cortex 
(vmPFC) increased, reflecting increased coupling 
between these areas (Heinz et al., 2005), whereas 
decreased coupling was found between the amygdala 
and the perigenual anterior cingulate cortex (pACC) 
(Pezawas et al., 2005). The s allele was also associ-
ated with alterations in frontal-limbic white matter 
microstructure indicating abnormalities in their con-
nectivity (Pacheco et al., 2009). These observations 
suggest that the top-down frontal cortical control on 
stress-, emotion-, and pain-processing limbic brain 
areas is under genetic control, and altered connection 
between these regions can be detected even before any 
symptoms develop. Thus these genes through these 
brain alterations can contribute to the development 
of both altered mood state and chronic or recurrent 
pain symptoms. 
In migraine, voxel-based morphometric studies 
(VBM) repeatedly found decreased grey matter 
volume in the pain network, including the ACC 
(May, 2009). These regions highly overlap with the 
stress response-processing networks. Decreased grey 
matter volume in the frontal lobe was associated with 
significantly slower response time during a cognitive 
task (set-shifting) in migraine patients (Schmitz et 
al., 2008). Altered top-down control of the visual 
cortex has been identified in migraine patients 
when attempting to suppress unattended visual 
events (Mickleborough et al., 2011). In addition, 
a diffusion-weighted MRI study demonstrated 
microstructural alterations in the right frontal 
white matter and its connection to the orbitofrontal 
cortex, insula, thalamus, dorsal midbrain (Szabo 
et al., 2012). In summary, several lines of evidence 
suggest that impaired frontal cortical control is 
present in migraine. It has been argued that these 
grey matter and microstructural changes might be 
secondary to repeated pain, as similar alterations can 
be observed in other chronic pain conditions (May, 
2009; Szabo et al., 2012). However, as we mentioned, 
the typical order of onset of symptoms is usually 
anxiety → migraine → depression. This suggests that 
impaired top-down frontal cortical control-elicited 
reduced stress resilience precedes the occurrence of 
repeated migraine pain and thus it can constitute 
an important mechanism in the development of 
comorbid depression and migraine.
A review collected the most important results of 
functional imaging studies of migraine (Schwedt and 
Chong, 2015). Evidence suggests that the migraine 
brain is hyperresponsive to different sensory stimuli, 
and there’s a potential imbalance of pain facilitation 
and inhibition within the migraine brain that possibly 
contributes to higher sensitivity to noxious stimuli 
and development of cutaneus allodynia during mi-
graine attacks. The authors mentioned that the ma-
jority of studies are cross-sectional, so direction of 
the found associations can’t be determined. Only a 
single longitudinal study suggested that the imaging 
abnormalities identified in migraine could be a result 
of recurrent migraine attacks. 
Some affective-motivational brain regions have 
been commonly identified with abnormal function 
or structure in migraineurs (including the anterior 
cingulate cortex, anterior insula, prefrontal cortex, 
hippocampus and amygdala), and imaging studies in 
people with psychiatric disorders (including depres-
sion) showed similar affected brain regions (Minen 
et al., 2016). A prospective longitudinal study fol-
lowed a sample from midlife to latelife and found 
that migraine with comorbid MDD is associated 
with reduced total brain volume, white matter vol-
ume, and gray matter volume (Gudmundsson et 
al., 2013). 
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THE ROLE OF STRESS IN THE COMORBIDITY 
OF MIGRAINE AND DEPRESSION
As seen above, biological factors are important in the 
connection of migraine and depression, biological 
factors, however cannot fully explain the comorbid-
ity of these two disorders. Thus we have to consider 
possible environmental and psychological factors 
contributing to this comorbidity. Many researchers 
indeed highlight the role of stress in this conversation.
A prospective longitudinal study (Swanson et 
al., 2013) examined the contribution of stress to the 
migraine-MDD comorbidity using several types of 
stressors (e.g., childhood trauma, marital and finan-
cial problems, work stress). The results supported the 
bidirectional connection between migraine and de-
pression, but both directions of this relationship were 
largely explained by stressors, and the associations 
were no longer significant after adjusting for all the 
measured stressor types. Importantly, all the studied 
stressors attenuated the associations, and the strong-
est risk factor was chronic stress for both disorders. 
A review on stress-migraine interaction (Sauro 
and Becker, 2009) defines the different possible roles 
of stress in this interaction. Stress can contribute to 
the onset of migraine, act as a trigger for migraine 
attacks and amplify their intensity and duration, and 
may also be a risk factor of migraine chronification. 
The authors also highlighted that migraine itself can 
be a stressor, creating a vicious cycle; and depression 
and anxiety can be considered as stressors too, be-
cause these states cause an imbalance of one’s homeo-
stasis, and share components with the physiological 
stress reaction. Stress is also connected with psychi-
atric disorders, and stressful events (especially early 
in life) increase the risk of MDD (Minen et al., 2016). 
A study (Hung et al., 2008) found that migraineurs 
with comorbid MDD are more sensitive to emotional 
and perceptual stimuli and stress of daily activities 
than patients with other headache types and comor-
bid MDD – suggesting a particularly important role of 
stress among migraineurs with comorbid depression.
Acute stress is necessary for survival and can be 
adaptive, but chronic stress leads to hyperalgesia and 
central sensitization (Sauro and Becker, 2009). In mi-
graine as a result of the repetead stress allostatic load 
occurs creating a feedforward cascade with altera-
tions in normal homeostatic mechanisms, failure to 
habituate to repeated stressors, and to normally shut 
down the stress response and inefficient response to 
stress (Borsook et al., 2012). Psychological factors 
(e.g., depression and anxiety) also play a role (among 
multiple processes) in the formation of altered al-
lostasis in migraine (Borsook et al., 2012). 
A study of a nationally representative U.S. sample 
of young adults tested whether emotional, sexual and 
physical abuse are associated with migraine, with and 
without accounting for other types of abuse and for 
comorbidities of depression and anxiety (Tietjen et 
al., 2017). Each type of abuse was consistently more 
frequent in migraineurs, and they were associated 
with significantly higher odds of migraine. In the 
fully adjusted model data supported a relationship 
beetween migraine and (only) emotional abuse, 
which was independent of (altough attenuated by) de-
pression and anxiety. Over two-thirds of participants 
reported that their diagnosis of migraine preceded or 
was concomittant with the diagnoses of depression 
and anxiety – the authors interpreted this finding as 
the adjustment for depression and anxiety might be 
an overcorrection. Abuse in the past possibly modi-
fies the hypothalamic-pituitary-adrenal (HPA) axis 
leading to higher stress reactivity, and through that 
strenghten the chance of migraine (Minen et al., 2016) 
and possibly also depression. 
PSYCHOLOGICAL FACTOR MEDIATING 
THE EFFECT OF STRESS IN DEPRESSION-
MIGRAINE COMORBIDITY
Most of the studies addressing psychological factors 
that contribute to distress in migraine focused on 
pain-related variables and general coping strategies, 
but not assessed stress-related psychological factors 
that are reliably associated with psychiatric disorders 
(Kokonyei et al., 2016). A recent study (Kokonyei et 
al., 2016) identified such a factor: rumination (a stable 
tendency to focus on distress-related feelings in a pas-
sive and repetitive way), which is strongly associated 
with depression and anxiety, partially mediated the 
relationship between migraine and psychological dis-
tress (controlling for lifetime depression). The authors 
speculated that rumination could increase allostatic 
load in migraine. 
Previously other personality traits have been im-
plicated in the comorbidity between depression and 
migraine. Neuroticism (emotional lability), a major 
risk factor for depression sharing part of its genetic 
background (Kendler et al., 2006) has been found to 
be associated with migraine (Breslau and Andreski, 
1995; Breslau et al., 1996), partly explained by the 
same genetic and nonshared environmental factors 
(Ligthart and Boomsma, 2012). These results suggest 
that neuroticism is a shared risk factor of migraine 
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and depression, and the level of neuroticism could be 
possibly remarkably high in patients with migraine 
and comorbid depression. Interestingly, rumination 
also mediates the connection between neuroticism 
and depression or anxiety (Kokonyei et al., 2016). 
Figure 1 summarizes the discussed shared factors 
of comorbid migraine and depression.
Figure 1. Shared factors of comorbid migraine and depression
THERAPEUTIC CONSIDERATIONS  
REGARDING THE COMORBIDITY OF 
MIGRAINE AND DEPRESSION
The strong connection between migraine and depres-
sion calls for some therapeutic considerations in the 
treatment of patients with this comorbidity. 
It’s recommended to screen for psychiatric disor-
ders in migraineurs (Minen et al., 2016), and given 
the bidirectional relationship between migraine and 
depression (and other psychiatric conditions), it could 
possibly also be recommended to screen for migraine 
in patients with psychiatric disorders, especially con-
sidering the fact that migraine is frequently under-
diagnosed and about half of migraine patients never 
received a diagnosis and proper treatment (Lipton 
and Bigal, 2007). The underdiagnosis of migraine 
could be particularly representative among men, be-
cause they are less likely to seek out medical advice 
for their migraine compared to women (Vetvik and 
MacGregor, 2017). 
We have seen that stress has a substantial role in 
the connection between depression and migraine, so 
use of stress-management techniques is important in 
these patients – some relevant techniques, includ-
ing relaxation training, cognitive behavioral therapy 
(CBT) adressing stress management, and biofeedback 
were consistently found to be effective in managing 
migraine (Sauro and Becker, 2009). Reducing rumina-
tion could be also a specific therapeutic target (Koko-
nyei et al., 2016). The combination of medication and 
behavioral treatment is more effective than either one 
alone in treating migraine (Minen et al., 2016), and 
probably also in the treatment of migraineurs with 
psychiatric comorbidities.
Autogenic training (AT) was shown to have a 
consistent and significant effect in reducing anxi-
ety (Ernst et al., 2007; Kanji et al., 2006; Manzoni et 
al., 2008) and it’s also effective as a preventive treat-
ment in migraine by decreasing migraine headache 
frequency after long term practice (Zsombok et al., 
2003; Zsombok et al., 2005), even though it cannot 
alleviate acute migraine pain (Juhasz et al., 2007). It 
can be assumed that the therapeutic potential of AT 
might also be relevant to prevent certain types of 
depression, especially in co-morbid migraine.
An important question is whether efficient treat-
ment of depression leads to a reduction also in the 
migraine symptoms (Ligthart et al., 2014), and vice 
versa: can succesful treatment of migraine reduce the 
comorbid psychiatric symptoms, too? The literature 
on the impact of comorbid psychiatric disorders on 
the effectiveness of headache treatment shows mixed 
results: some suggests that psychiatric comorbidities 
could lead to a failure of migraine treatment, while 
others report similar improvement rates after treat-
ment comparing patients with and without psychiatric 
comorbidities (Minen et al., 2016). There is evidence 
that prophylactic use of onabotulinumtoxin A signifi-
cantly reduced headache-related as well as depres-
sion and anxiety symptoms in patients with chronic 
migraine and comorbid depression (Boudreau et al., 
2015). Another promising example is that a treatment 
program using CBT among patients with migraine 
and/or tension-type headache and comorbid MDD 
improved participants’ headache symptoms, depres-
sion, anxiety and quality of life, and these improve-
ments were maintained at least for 4 months (Martin 
et al., 2015).
CONCLUSION
In this review we focused on the connection be-
tween migraine and depression, however, there is 
also evidence for the assocation between migraine 
and other psychiatric (and somatic) disorders. For 
example, post-traumatic stress disorder (PTSD) is 
also significantly more prevalent among migraineurs 
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than in the general population, and there are also 
data suggesting that PTSD mediates the association 
between abuse and migraine (Minen et al., 2016). 
We also need to highlight that both migraine and 
depression shows high disease heterogeneity, and 
the biological aspect of the comorbidity between the 
two conditions could vary diagnosis by diagnosis. 
There’s clearly a need to recognize the potential sub-
groups of this heterogenous patient population, and 
to stratify the possibly different biological pathways 
in the background of their conditions towards the 
way of precision medicine.
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A migrén és a depresszió jól ismerten kapcsolódik egymáshoz. A mindkét betegséget mutató 
betegek a fejfájáshoz köthető erősebb tüneteket és súlyosabb klinikai lefolyást mutatnak, 
valamint körükben nagyobb a migrén krónikussá válásának kockázata. Mindebből adódó-
an fontos a komorbid migrén és depresszió hátterében meghúzódó faktorok azonosítása. 
Az egyre növekvő szakirodalom komplex, biopszichoszociális mechanizmusokra utal a jelenség 
hátterében, beleértve közös genetikai rizikófaktorokat és kóros agyi mechanizmusokat, illetve 
különféle környezeti (stressz) és pszichológiai (például: rumináció, neuroticizmus) tényezőket 
egyaránt. Rövid összefoglalónkban összegezzük az együttesen jelentkező migrén és depresz-
szió patomechanizmusában egymással interakcióban szerepet játszó faktorokkal kapcsolatos 
legfontosabb szakirodalmi eredményeket. Végül néhány terápiás megfontolást is közlünk 
a migrén-depresszió fenotípust mutató alanyok kezelése kapcsán.
Kulcsszavak: migrén, depresszió, komorbiditás, genetika, agyi mechanizmusok, stressz, 
rumináció, terápia, összefoglaló
Miért gyakoribb a depresszió migrénesekben?
A migrén és a depresszió komorbiditásához járuló faktorok  
áttekintése 
